Background: The mesothelium contributes significantly to the functional, structural and homeostatic properties of the peritoneum. Bioincompatible peritoneal dialysis solutions contribute to mesothelial cell loss during chronic peritoneal dialysis. Cell death has been implicated in mesothelial cell loss, but the molecular mechanisms have not been adequately characterized. We now report the modulation of mesothelial cell death by the glucose degradation product 3,4-dideoxyglucosone-3-ene (3,4-DGE).
Methods: Human mesothelial cells were cultured from the effluents of stable dialysis patients. Apoptosis was quantified in cultured mesothelial cells and in peritoneal effluents. Confocal microscopy and inhibitors were used to assess molecular mechanisms.
Results: Peritoneal dialysis solutions with a high content of both glucose and glucose degradation products, but not those with low glucose degradation product content, induced mesothelial cell apoptosis and loss of cell viability in culture and in vivo. 3,4-DGE also induced mesothelial cell apoptosis. Apoptosis induced by peritoneal dialysis solutions and 3,4-DGE was associated with oligomerization of Bax at mitochondria and caspase activation. Bax antagonism prevented caspase activation, apoptosis and cell death. The pancaspase inhibitor zVAD was also protective.
Conclusion: 3,4-DGE and peritoneal dialysis solutions with a high content in glucose degradation products induce mesothelial cell apoptosis by a Bax-dependent mechanism. This could contribute to chronic demesothelization in peritoneal dialysis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/ndt/gfn273 | DOI Listing |
Pediatr Int
January 2025
Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan.
Perit Dial Int
January 2025
Division of Nephrology, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
There is growing emphasis on increasing utilization of peritoneal dialysis (PD) in patients with end stage kidney disease (ESKD); however, use in patients with severe obesity has still been fraught for various reasons. We aim to assess the viability of PD in patients with severe obesity (BMI > 40 Kg/m). We conducted a retrospective chart review of patients admitted at the home dialysis center of an academic center between 2014 and 2020 (n = 99).
View Article and Find Full Text PDFCureus
December 2024
Nephrology, Hospital Regional Hans Dieter Schmidt, Joinville, BRA.
Fungal peritonitis is an uncommon but serious complication that can occur in patients undergoing peritoneal dialysis. It represents a small percentage of all peritonitis cases in these patients. Its diagnosis can be challenging due to the slow growth of fungi and frequent negative culture results.
View Article and Find Full Text PDFSci Rep
January 2025
Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Preservation of residual kidney function (RKF) is important in patients undergoing peritoneal dialysis (PD). We aimed to examine the association between anemia management and residual urine output using data from a nationwide survey of dialysis patients. After excluding patients with anuria at baseline from the Total cohort of 2,712, 659 of 1,640 patients developed anuria during a median follow-up of 2.
View Article and Find Full Text PDFPerit Dial Int
January 2025
Renal Physiology and Dialysis Group, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!